Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg plus prednisone vs prednisone in newly diagnosed myositis
2020-001710-37Phase 3Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autoimmune Myopathies comparing IVIg (Nanogam) + prednisone with Prednisone + placebo (2 arms). Primary endpoint: Total Improvement Score at 8 weeks. Started Jan 2021; status: active.
02
Drugs
Nanogamprednisone
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on 2020-001710-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001710-37.